Saturday 17 October 2026
Export PRQR’s income statement to Excel — free account
ProQR Therapeutics N.V.
PRQR Healthcare Biotechnology
ProQR Therapeutics N.V.’s revenue for fiscal 2025 (year ended December 2025) was $18.0 million, down 12.0% from fiscal 2024. In the quarter to June 2026, revenue grew 135.0%, EPS grew 28.6%, free cash flow fell 1.06% and total debt rose 8.71%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.31
0.14
−9.66%
Follow PRQR
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
13.14 | 11.82 | 10.93 | 9.53 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(14.74) | (15.61) | (13.09) | (14.42) | |
P/B ratio |
3.36 | 3.81 | 3.88 | 2.21 | |
Price to Tangible BV |
3.37 | 3.81 | 3.88 | 2.21 | |
EV/Sales |
6.43 | 6.58 | 5.52 | 3.67 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.97) | (1.98) | (1.54) | (1.41) | |
EV/FCF |
(1.94) | (1.94) | (1.51) | (1.37) | |
Quick Ratio |
3.23 | 3.06 | 2.44 | 3.47 | |
Current Ratio |
3.36 | 3.09 | 2.48 | 3.49 | |
Net Debt/EBITDA |
9.65 | 9.93 | 5.88 | 13.81 | |
Debt/Assets |
3.86% | 4.32% | 4.99% | 3.76% | |
Debt/Equity |
0.08 | 0.10 | 0.13 | 0.06 | |
Asset Turnover |
0.13 | 0.12 | 0.11 | 0.14 | |
Operating CF/Net income |
1.18 | 1.31 | 0.83 | 1.40 | |
Capex/Depreciation |
(0.25) | (0.83) | (0.24) | (0.41) | |
Research and Development Expense of Revenue |
384.45% | 211.93% | 581.90% | 144.62% | |
Selling, General and Administrative Expense of Revenue |
108.22% | 81.66% | 189.48% | 56.10% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
40.42% | 23.26% | 70.24% | 15.40% | |
Graham Net Nets |
0.23 | 0.20 | 0.18 | 0.38 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(22.07%) | (22.77%) | (30.86%) | (24.73%) | |
Free Cash Flow Yield |
(25.15%) | (28.61%) | (33.53%) | (28.06%) | |
Revenue per Share |
0.03 | 0.05 | 0.02 | 0.09 | |
Operating CF per Share |
(0.14) | (0.13) | (0.12) | (0.13) | |
Capex per Share |
0.00 | (0.01) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.15) | (0.13) | (0.13) | (0.13) | |
Cash per Share |
1.19 | 0.99 | 0.90 | 1.24 | |
Shareholders Equity per Share |
0.63 | 0.53 | 0.42 | 0.84 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.63 | 0.53 | 0.42 | 0.84 | |
Free Cash Flow |
(15.43) | (14.21) | (13.24) | (14.52) | |
Working Capital |
91.40 | 76.58 | 60.77 | 100.87 | |
Capital Expenditures |
(0.21) | (0.58) | (0.19) | (0.34) | |
Net Current Asset Value |
51.49 | 41.57 | 29.90 | 78.55 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.06 | 0.10 | 0.08 | 0.03 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | 34.39 | 2.83 | 2.49 | |
Average Payables |
0.20 | 0.18 | 0.33 | — | |
Average Assets |
131.42 | 154.66 | 137.86 | 155.71 | |
Average Common Equity |
47.09 | 75.85 | 63.58 | 84.22 |
Columns are period end dates